Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
24 hedge funds and large institutions have $71.6M invested in Iterum Therapeutics in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.17% more ownership
Funds ownership: 0% → 3.17% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$20.8M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$18.5M |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
+$17.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.02M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.63M |
Top Sellers
ITRM Hedge Fund Activity: Q2 2018 in Review
24 of the 4,344 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q2 2018, worth a combined $71.6M.
Buyers outnumbered sellers: 24 funds opened new ITRM positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sofinnova Investments, opening a new position worth an estimated $20.8M.
- 24 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $71.6M of Iterum Therapeutics stock for Q2 2018.
- 24 funds opened new Iterum Therapeutics positions in Q2 2018 and 0 closed out, a net change of +24 holders.
- The largest Iterum Therapeutics buyer in Q2 2018 was Sofinnova Investments, an estimated $20.8M added.
Based on aggregated 13F filings for Q2 2018.